Autologous natural killer cells as a promising immunotherapy for locally advanced colon adenocarcinoma: Three years follow‐up of resectable case

BACKGROUND: Over the last decade, a new modality of immunotherapy has been announced, with the expectation of better long‐term clinical outcomes and disease‐free survival after the definitive surgical treatment of colon cancer. Natural killer (NK) cells as part of cellular therapy in immunotherapy have the potential effect as an adjuvant therapy for locally advanced and metastasized colorectal adenocarcinoma. We would evaluate the clinical outcome of autologous NK cell therapy for resectable colon cancer. CASE: A 64‐year‐old woman presented with a transverse colon tumor‐related partial intestinal obstruction and a history of bloody diarrhea. A transverse colectomy has been done, and the pathology report reported adenocarcinoma of the transverse colon and positive lymph node involvement (TNM stage III). The patient had R0 resection status. A PET scan was done 6 months later, with positive lymph node glucose uptake at mesocolic. NK cell therapy was administered for 2 cycles with a 3‐month interval, and PET scan follow‐up was done 3 years after resection; no more glucose uptake was found, and the patients tolerated the therapy well with no immune‐related adverse effects reported. CONCLUSION: As a new modality in immunotherapy strategies for locally advanced colon adenocarcinoma, particularly in cases unsuitable for standard chemotherapeutic treatment, autologous NK cells have a promising effect and are feasible and well tolerated in our clinical practice.